Compare PDYN & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDYN | CABA |
|---|---|---|
| Founded | 1983 | 2017 |
| Country | United States | United States |
| Employees | 70 | N/A |
| Industry | Wholesale Distributors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 292.0M | 319.6M |
| IPO Year | N/A | 2019 |
| Metric | PDYN | CABA |
|---|---|---|
| Price | $7.11 | $2.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $9.67 | ★ $14.50 |
| AVG Volume (30 Days) | 2.0M | ★ 3.4M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $384.48 | N/A |
| Revenue Next Year | $63.16 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.14 | $1.26 |
| 52 Week High | $12.79 | $4.23 |
| Indicator | PDYN | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 51.70 | 34.39 |
| Support Level | $5.89 | $2.58 |
| Resistance Level | $7.77 | $3.48 |
| Average True Range (ATR) | 0.79 | 0.27 |
| MACD | -0.14 | -0.08 |
| Stochastic Oscillator | 36.46 | 7.76 |
Palladyne AI Corp is a software company focused on autonomy for robotic systems and solutions. Its artificial intelligence and machine learning software seeks to revolutionize the capabilities of robots, enabling them to observe, learn, reason, and act in structured and unstructured environments. AI and ML software platform of the company empowers robots to perceive variations or changes in the real-world environment, enabling them to autonomously maneuver and manipulate objects accurately in response. Palladyne AI software has wide application, including in industries such as automotive, aviation, construction, defense, general manufacturing, infrastructure inspection, logistics and warehousing.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.